Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADAM JONATHAN KAPLAN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1245322056
CMS profile
328332
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,073.94

82 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,073.94 82

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADAM JONATHAN KAPLAN

NPI 1245322056 · CMS profile ID 328332

Allopathic & Osteopathic Physicians / Family Medicine

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245322056?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADAM JONATHAN KAPLAN, NPI 1245322056, CMS profile ID 328332. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245322056?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ADAM JONATHAN KAPLAN, NPI 1245322056, CMS profile ID 328332. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245322056?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ADAM JONATHAN KAPLAN, NPI 1245322056, CMS profile ID 328332, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1245322056?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

82 matching records · $1,073.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 82 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–82 of 82.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $17.6707/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747746837 CMS
GlaxoSmithKline, LLC. $11.8306/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738475899 CMS
SANOFI-AVENTIS U.S. LLC $11.1106/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744171517 CMS
Eisai Inc. $16.5006/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751345125 CMS
Novo Nordisk Inc $14.3406/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744774263 CMS
Novo Nordisk Inc $13.4406/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744739737 CMS
Novo Nordisk Inc $3.8106/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744700967 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.0505/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720491503 CMS
SANOFI-AVENTIS U.S. LLC $21.0505/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744171509 CMS
AstraZeneca Pharmaceuticals LP $15.9705/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736261779 CMS
Novo Nordisk Inc $13.1905/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744691569 CMS
VIVUS, Inc. $13.6905/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736580287 CMS
Novo Nordisk Inc $12.0405/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744693277 CMS
Currax Pharmaceuticals LLC $11.5205/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739120695 CMS
AstraZeneca Pharmaceuticals LP $12.3505/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735806205 CMS
Novo Nordisk Inc $3.8505/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744677171 CMS
Novo Nordisk Inc $3.8504/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744665767 CMS
Novo Nordisk Inc $14.8204/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744665755 CMS
Currax Pharmaceuticals LLC $12.5504/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739120689 CMS
Novo Nordisk Inc $14.5004/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744655335 CMS
Novo Nordisk Inc $4.3603/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744633483 CMS
Novo Nordisk Inc $14.5602/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744609769 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.2502/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747224123 CMS
Merck Sharp & Dohme Corporation $15.2202/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747689253 CMS
Novo Nordisk Inc $12.3402/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744585417 CMS
Novo Nordisk Inc $4.8502/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744588903 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.7802/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720491507 CMS
Genentech USA, Inc. $18.5601/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742972325 CMS
Currax Pharmaceuticals LLC $11.8001/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739120681 CMS
GlaxoSmithKline, LLC. $12.7801/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738476221 CMS
AstraZeneca Pharmaceuticals LP $11.2901/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736246885 CMS
Novo Nordisk Inc $10.2701/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744562281 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $803.43 64
PY2020 $1,073.94 82
PY2021 $1,204.96 83
PY2022 $658.97 44
PY2023 $510.84 32
PY2024 $854.69 50
PY2025 $884.80 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $426,951.29 137
PY2024 Principal investigator $526,395.81 18
PY2023 Principal investigator $22,545.45 18
PY2022 Principal investigator $65,407.04 22
PY2021 Principal investigator $56,014.05 25
PY2020 Principal investigator $67,307.76 19
PY2019 Principal investigator $58,211.55 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

137 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seqirus USA Inc $436.05 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263483
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263515
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263517
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263519
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263521
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263523
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263525
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263527
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263529
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263531
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263533
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263535
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263537
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263539
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263541
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263543
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263546
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263549
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263551
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263553
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263555
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263557
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263559
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263561
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263563
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263566
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263569
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263571
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263575
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263577
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263579
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263583
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263585
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263587
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263589
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263591
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263593
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263595
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263597
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263599
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263601
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263603
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263605
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263607
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263609
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263611
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263613
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263615
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263617
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263619
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263621
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263623
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263625
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263627
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263629
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263631
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263633
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263635
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263637
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263639
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263641
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263643
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263645
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263647
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263649
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263651
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263653
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263655
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263657
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263661
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263663
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263665
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263667
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263669
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263671
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263673
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263675
Principal investigator 1 Seqirus USA Inc $3,324.38 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263677
Principal investigator 1 Seqirus USA Inc $436.05 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263697
Principal investigator 1 Seqirus USA Inc $436.05 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263699
Principal investigator 1 Seqirus USA Inc $436.05 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263701
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263703
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263705
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263707
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263709
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263711
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263713
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263715
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263717
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263719
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263721
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263723
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263725
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263727
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263729
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263731
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263733
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263735
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263737
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263739
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263741
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263743
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263745
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263747
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264015
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264017
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264019
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264021
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264023
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264025
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264027
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264029
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264031
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264036
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264039
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264041
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264043
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264045
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264047
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264049
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264051
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264053
Principal investigator 1 Seqirus USA Inc $1,154.25 12/18/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264055
Principal investigator 1 Seqirus USA Inc $3,846.60 11/13/2025 Non-covered Recipient Entity
ACRC Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810584
Principal investigator 1 Seqirus USA Inc $1,057.05 11/13/2025 Non-covered Recipient Entity
ACRC Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810590
Principal investigator 1 Seqirus USA Inc $3,419.20 10/31/2025 Non-covered Recipient Entity
ACRC Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810564
Principal investigator 1 Seqirus USA Inc $939.60 10/31/2025 Non-covered Recipient Entity
ACRC Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810569
Principal investigator 1 Seqirus USA Inc $9,500.00 10/13/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264009
Principal investigator 1 Seqirus USA Inc $2,500.00 10/08/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185264011
Principal investigator 1 Seqirus USA Inc $110.98 09/09/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263987
Principal investigator 1 Seqirus USA Inc $111.30 09/09/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263991
Principal investigator 1 Seqirus USA Inc $946.80 09/09/2025 Non-covered Recipient Entity
Marwah Investments Corporation
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185263997
Principal investigator 1 PFIZER INC. $3,412.80 07/29/2025 Non-covered Recipient Entity
ACRC TRIALSNorth Texas Family Medicine
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228716393
Principal investigator 1 GlaxoSmithKline, LLC. $1,417.00 02/12/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1192110901
Principal investigator 1 GlaxoSmithKline, LLC. $13,473.00 02/12/2025 Non-covered Recipient Entity
MARWAH INVESTMENTS CORP DBA ACR
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1192110908
Principal investigator 1 PFIZER INC. $38,225.00 01/22/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228723030
Principal investigator 1 PFIZER INC. $41,792.00 01/15/2025 Non-covered Recipient Entity
Marwah Investments Corporation dba ACRC Trials
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228720521